Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, warns the WHO as it publishes its initial advice on the drugs.
Considering more than one billion people worldwide now obese, it is urging increased and just access to GLP-1 medication.
Based on estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant hurdles to broad access to the injections that can assist patients in reducing significant weight, says the organization.
Skinny Jab Shortage
Even in the present most favorable scenario, the production of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, per the WHO.
The guideline encourages governments and firms to increase availability, via strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is scheduled to end in several countries in 2026.
The Way Weight-Loss Injections Operate
These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase satiety so individuals eat less.
Individuals commonly start to lose weight within a few weeks of starting on the regular doses.
Research indicates patients may see weight return a year later of halting the medication, because their typical food cravings come back.
Being above a healthy weight increases your likelihood for experiencing diseases, including diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
